Racemic Ketamine Vs R-Ketamine Vs S-Ketamine: What You Need to Know | Isha Health

Understanding Ketamine and Its Role in Mental Health Treatment

Ketamine has gained significant attention in recent years as a breakthrough treatment for mental health disorders such as depression, bipolar disorder, anxiety, and PTSD. Originally developed as a dissociative anesthetic, ketamine’s antidepressant effects have reshaped its role in modern medicine. However, not all forms of ketamine are the same.

Ketamine is a chiral molecule, meaning it has two mirror-image forms or enantiomers: R-Ketamine and S-Ketamine. Think of them like your hands: they look similar but cannot be perfectly superimposed. When these enantiomers are combined in equal parts, the result is Racemic Ketamine. Each form has distinct therapeutic properties, and understanding these differences is critical for optimizing ketamine-assisted therapy.

In this article, we’ll dive into the unique characteristics, effects, and clinical applications of Racemic Ketamine, R-Ketamine, and S-Ketamine, helping you make informed decisions about your mental health journey.

‍

A Brief History of Ketamine

Ketamine’s story begins in the 1960s when Dr. Stevens at Wayne State University synthesized Racemic Ketamine as a short-acting anesthetic. By 1970, it had gained FDA approval for use in anesthesia. Over the next few decades, researchers uncovered its potential as a powerful antidepressant.

In 2000, Dr. Berman and colleagues conducted a groundbreaking study demonstrating ketamine’s rapid antidepressant effects in patients with Major Depressive Disorder (MDD). This was followed by Dr. Zarate’s research in 2006, which highlighted its efficacy in treatment-resistant depression (TRD). These studies paved the way for ketamine’s modern role in mental health treatment.

‍

What is Racemic Ketamine?

A Balanced Mixture

Racemic Ketamine contains equal parts of R-Ketamine and S-Ketamine. It has been used clinically since the 1960s, primarily as an anesthetic. Today, it is widely used off-label for mental health conditions, particularly treatment-resistant depression (TRD), bipolar disorder, and PTSD.

‍

How It Works

Imagine ketamine as a key that fits into specific locks in your brain. These locks are called receptors, and they help regulate your mood and stress levels. Racemic Ketamine works by affecting these locks, particularly NMDA and AMPA receptors, which are involved in how the brain processes emotions and adapts to stress. It also boosts the production of proteins that help brain cells grow and connect, like Brain-Derived Neurotrophic Factor (BDNF).

‍

Clinical Evidence

Studies show that Racemic Ketamine produces rapid and significant improvements in mood, often within hours—far faster than traditional antidepressants. However, it may cause temporary side effects such as dissociation (a feeling of being detached from reality), hallucinations, and dizziness. These effects usually wear off quickly.

‍

What is R-Ketamine?

The Gentler Enantiomer

R-Ketamine, the “right-hand” enantiomer, has been found to produce longer-lasting antidepressant effects with fewer side effects than Racemic Ketamine. It is particularly effective in:

• Reducing symptoms of depression.
• Enhancing synaptic connectivity in the brain.

‍

Clinical Advantages

R-Ketamine is associated with:

• Fewer dissociative effects, making it a more tolerable option for patients.
• Improved neuroplasticity, particularly in the prefrontal cortex and hippocampus, which are critical for mood regulation and cognitive function.

Think of R-Ketamine as a slow-burning fuel: it takes longer to act, but its effects last longer and are easier on the body.

A study in Translational Psychiatry highlights that R-Ketamine produces greater potency and longer-lasting antidepressant effects than S-Ketamine, with fewer psychotomimetic side effects.

‍

What is S-Ketamine?

FDA-Approved Innovation

S-Ketamine, or esketamine, is the "left-hand" enantiomer and is best known for its FDA-approved nasal spray, Spravato, used to treat treatment-resistant depression. It is approximately four times more potent than R-Ketamine in blocking NMDA receptors.

How It Works

S-Ketamine’s antidepressant effects are thought to involve boosting certain brain chemicals that help improve mood quickly. This is why S-Ketamine can offer relief within hours for some patients, making it a lifesaving option for those struggling with severe depression or suicidal thoughts.

Clinical Considerations

While highly effective for rapid symptom relief, S-Ketamine’s higher potency may lead to more pronounced side effects, including dissociation and dizziness. Its addictive potential necessitates strict regulation, and it is administered only in certified healthcare settings.

‍

‍

Ketamine Types and Forms

Ketamine is available in various forms, each with its specific uses and benefits:

• Racemic Ketamine: The most common form used in IV infusions for depression and pain management.
• S-Ketamine (Esketamine): Available as a nasal spray (Spravato), designed for treatment-resistant depression.
• R-Ketamine: Not FDA-approved but gaining attention for its longer-lasting effects and fewer side effects.

Additionally, ketamine is sometimes referred to by colloquial terms such as "ketamine shards," highlighting its appearance in certain formulations, though these terms are less relevant in medical settings.

‍

Neuroplasticity: A Key Difference

What is Neuroplasticity?

Neuroplasticity refers to the brain's ability to form new connections and adapt to changes. It’s like your brain’s way of rewiring itself to better handle challenges. This rewiring is critical for improving mood and managing mental health conditions like depression and PTSD.

‍

R-Ketamine vs. S-Ketamine

• R-Ketamine: Strongly promotes synaptogenesis (formation of new connections) in the prefrontal cortex and hippocampus, contributing to sustained antidepressant effects.
• S-Ketamine: Boosts BDNF production, which supports the growth and survival of neurons.

Both enantiomers offer unique pathways to improving brain health, but their effects on neuroplasticity differ significantly. Think of R-Ketamine as building stronger bridges between brain cells, while S-Ketamine focuses on growing new connections quickly.

‍

FAQs About Ketamine Therapy

1. How is R-Ketamine different from S-Ketamine in therapy? R-Ketamine tends to have longer-lasting effects with fewer side effects, while S-Ketamine provides rapid symptom relief but may cause stronger dissociative effects.

2. Which form of ketamine is safer? Both forms are safe when administered under medical supervision. However, R-Ketamine may be more tolerable for patients sensitive to dissociation.

3. Is ketamine therapy covered by insurance? S-Ketamine (Spravato) is FDA-approved and often covered by insurance, while R-Ketamine and Racemic Ketamine are used off-label and may require out-of-pocket payment.

4. What are "R" and "S" types of ketamine? R and S refer to the two enantiomers of ketamine. These forms differ in how they interact with the brain, leading to variations in effects and side effects.

‍

Choosing the Right Ketamine-Assisted Therapy

When considering ketamine-assisted therapy, it’s essential to work with a qualified provider to determine the best option for your needs. Factors to consider include:

• Your Mental Health Goals: Are you looking for rapid relief or long-lasting effects?
• Tolerability: Are you sensitive to dissociation or other side effects?
• Cost and Accessibility: S-Ketamine is FDA-approved and covered by insurance in some cases, while R-Ketamine and Racemic Ketamine are often used off-label.

At Isha Health, we offer personalized ketamine-assisted therapy designed to help you achieve lasting mental health improvement. Our licensed professionals provide safe, effective care tailored to your individual needs.

‍

Conclusion

Ketamine’s role in mental health treatment is a game-changer, but understanding the differences between Racemic Ketamine, R-Ketamine, and S-Ketamine is crucial for making informed decisions. Each form offers unique benefits and challenges, and working with a knowledgeable provider can help you maximize the therapeutic potential of ketamine.

If you’re ready to explore ketamine-assisted therapy, contact us at Isha Health to start your journey toward better mental health.

‍

References:

1. Lener MS, Kadriu B, Zarate Jr. CA. Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression. Drugs. 2017;77(4):381-401. doi: 10.1007/s40265-017-0700-7
2. Andrade C. Ketamine for depression, 4: In what dose, at what rate, by what route, for how long, and at what frequency? J Clin Psychiatry. 2017;78(7):e852-e857. doi: 10.4088/JCP.17f11772
3. Schak KM, Vande Voort JL, Johnson Jr. KA, et al. A retrospective analysis of intravenous ketamine for treatment-resistant depression. Clin Neuropharmacol. 2016;39(6):318-321. doi: 10.1097/WNF.0000000000000194
4. Singh JB, Fedgchin M, Daly EJ, et al. A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression. Am J Psychiatry. 2016;173(8):816-826. doi: 10.1176/appi.ajp.2016.16010037
5. McIntyre RS, Filteau MJ, Martin L, et al. Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach. J Affect Disord. 2014;156:1-7. doi: 10.1016/j.jad.2013.10.043
6. Singh JB, Fedgchin M, Daly EJ, et al. Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study. Biol Psychiatry. 2016;80(6):424-431. doi: 10.1016/j.biopsych.2015.10.018
7. Zhou W, Wang N, Yang C, et al. Rapid and Longer-Term Antidepressant Effects of Repeated-Dose Intravenous Ketamine for Patients With Unipolar and Bipolar Depression. J Psychiatr Res. 2018;106:61-68. doi: 10.1016/j.jpsychires.2018.09.013
8. Grunebaum MF, Galfalvy HC, Choo TH, et al. Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial. Am J Psychiatry. 2018;175(4):327-335. doi: 10.1176/appi.ajp.2017.17060647
9. Schwartz J, Murrough JW, Iosifescu DV. Ketamine for treatment-resistant depression: recent developments and clinical applications. Evid Based Ment Health. 2016;19(2):35-38. doi: 10.1136/eb-2016-102348
10. Kishimoto T, Chawla JM, Hagi K, et al. Single-dose infusion ketamine and non-ketamine N-methyl-D-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories. Psychol Med. 2016;46(7):1459-1472. doi: 10.1017/S0033291716000293